These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 17356390

  • 21. Determinants of progression from microalbuminuria to proteinuria in patients who have type 1 diabetes and are treated with angiotensin-converting enzyme inhibitors.
    Ficociello LH, Perkins BA, Silva KH, Finkelstein DM, Ignatowska-Switalska H, Gaciong Z, Cupples LA, Aschengrau A, Warram JH, Krolewski AS.
    Clin J Am Soc Nephrol; 2007 May; 2(3):461-9. PubMed ID: 17699452
    [Abstract] [Full Text] [Related]

  • 22. IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria.
    Coppo R, Peruzzi L, Amore A, Piccoli A, Cochat P, Stone R, Kirschstein M, Linné T.
    J Am Soc Nephrol; 2007 Jun; 18(6):1880-8. PubMed ID: 17513327
    [Abstract] [Full Text] [Related]

  • 23. Fractional urinary excretion of IgG is the most powerful predictor of renoprotection by ACE inhibitors in IgA nephropathy.
    Bazzi C, Rizza V, Paparella M, Casellato D, Napodano P, Olivieri G, D'Amico G.
    J Nephrol; 2009 Jun; 22(3):387-96. PubMed ID: 19557716
    [Abstract] [Full Text] [Related]

  • 24. Enalapril reduces the albuminuria of patients with sickle cell disease.
    Aoki RY, Saad ST.
    Am J Med; 1995 May; 98(5):432-5. PubMed ID: 7733120
    [Abstract] [Full Text] [Related]

  • 25. Incidence and natural history of proliferative sickle cell retinopathy: observations from a cohort study.
    Downes SM, Hambleton IR, Chuang EL, Lois N, Serjeant GR, Bird AC.
    Ophthalmology; 2005 Nov; 112(11):1869-75. PubMed ID: 16171867
    [Abstract] [Full Text] [Related]

  • 26. Cardiorenal risk prevalence in sickle cell hemoglobinopathy.
    Abo-Zenah H, Moharram M, El Nahas AM.
    Nephron Clin Pract; 2009 Nov; 112(2):c98-c106. PubMed ID: 19390209
    [Abstract] [Full Text] [Related]

  • 27. Clinical response and adverse events in young patients with sickle cell disease treated with hydroxyurea.
    Kattamis A, Lagona E, Orfanou I, Psichou F, Ladis V, Kanavakis E, Metaxotou-Mavrommati A, Kattamis C.
    Pediatr Hematol Oncol; 2004 Jun; 21(4):335-42. PubMed ID: 15205096
    [Abstract] [Full Text] [Related]

  • 28. Characterization of S-glutathionyl hemoglobin in homozygous sickle cell disease.
    Thom GG, Kallanagowdar C, Somjee SS, Velez MC, Yu LC, Hempe JM.
    J Pediatr Hematol Oncol; 2009 Dec; 31(12):895-900. PubMed ID: 19855306
    [Abstract] [Full Text] [Related]

  • 29. Follow-up of sickle cell disease patients with priapism treated by hydroxyurea.
    Saad ST, Lajolo C, Gilli S, Marques Júnior JF, Lima CS, Costa FF, Arruda VR.
    Am J Hematol; 2004 Sep; 77(1):45-9. PubMed ID: 15307105
    [Abstract] [Full Text] [Related]

  • 30. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, McMahon RP, Bonds DR.
    N Engl J Med; 1995 May 18; 332(20):1317-22. PubMed ID: 7715639
    [Abstract] [Full Text] [Related]

  • 31. Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial.
    Ruggenenti P, Perna A, Ganeva M, Ene-Iordache B, Remuzzi G, BENEDICT Study Group.
    J Am Soc Nephrol; 2006 Dec 18; 17(12):3472-81. PubMed ID: 17082240
    [Abstract] [Full Text] [Related]

  • 32. Fetal hemoglobin response to hydroxyurea in Yemeni sickle cell disease patients.
    Al-Nood HA, Al-Khawlani MM, Al-Akwa A.
    Hemoglobin; 2011 Dec 18; 35(1):13-21. PubMed ID: 21250877
    [Abstract] [Full Text] [Related]

  • 33. Hodgkin's disease in a child with sickle cell disease treated with hydroxyurea.
    Moschovi M, Psychou F, Menegas D, Tsangaris GT, Tzortzatou-Stathopoulou F, Nicolaidou P.
    Pediatr Hematol Oncol; 2001 Sep 18; 18(6):371-6. PubMed ID: 11554231
    [Abstract] [Full Text] [Related]

  • 34. Prevalence and clinical correlates of microalbuminuria in children with sickle cell disease.
    Becton LJ, Kalpatthi RV, Rackoff E, Disco D, Orak JK, Jackson SM, Shatat IF.
    Pediatr Nephrol; 2010 Aug 18; 25(8):1505-11. PubMed ID: 20505954
    [Abstract] [Full Text] [Related]

  • 35. Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease.
    Kent DM, Jafar TH, Hayward RA, Tighiouart H, Landa M, de Jong P, de Zeeuw D, Remuzzi G, Kamper AL, Levey AS.
    J Am Soc Nephrol; 2007 Jun 18; 18(6):1959-65. PubMed ID: 17475813
    [Abstract] [Full Text] [Related]

  • 36. Hydroxyurea treatment in children with sickle cell anemia in Central America and the Caribbean countries.
    Svarch E, Machín S, Nieves RM, Mancia de Reyes AG, Navarrete M, Rodríguez H.
    Pediatr Blood Cancer; 2006 Jul 18; 47(1):111-2. PubMed ID: 16550531
    [No Abstract] [Full Text] [Related]

  • 37. Glomerular involvement in adults with sickle cell hemoglobinopathies: Prevalence and clinical correlates of progressive renal failure.
    Guasch A, Navarrete J, Nass K, Zayas CF.
    J Am Soc Nephrol; 2006 Aug 18; 17(8):2228-35. PubMed ID: 16837635
    [Abstract] [Full Text] [Related]

  • 38. Hydroxyurea therapy associated with declining serum levels of magnesium in children with sickle cell anemia.
    Altura RA, Wang WC, Wynn L, Altura BM, Altura BT.
    J Pediatr; 2002 May 18; 140(5):565-9. PubMed ID: 12032523
    [Abstract] [Full Text] [Related]

  • 39. Long-term hydroxyurea treatment in children with sickle cell disease: tolerance and clinical outcomes.
    de Montalembert M, Brousse V, Elie C, Bernaudin F, Shi J, Landais P, French Study Group on Sickle Cell Disease.
    Haematologica; 2006 Jan 18; 91(1):125-8. PubMed ID: 16434381
    [Abstract] [Full Text] [Related]

  • 40. Use of hydroxyurea in children with sickle cell disease: what comes next?
    Ohene-Frempong K, Smith-Whitley K.
    Semin Hematol; 1997 Jul 18; 34(3 Suppl 3):30-41. PubMed ID: 9317199
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.